Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Post-transplant cyclophosphamide, tacrolimus, and MMF for GvHD in the myeloablative setting

Shernan Holtan • 10 Dec 2022
ASH 2022
General Cyclophosphamide Mycophenolate mofetil Tacrolimus
BMT CTN 1703

Shernan Holtan, MD, University of Minnesota, Minneapolis, MN, briefly discusses the results of a Phase II study evaluating post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil (MMF) for graft-versus-host disease (GvHD) in the myeloablative transplant setting. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Incyte: Research Funding; Vitrac Therapeutics: Research Funding; CSL Behring: Other: Clinical trial adjudication.

More from Shernan Holtan

1:05
Unmet needs in GvHD & the promise of regenerative medicine
Shernan Holtan • 10 Dec 2022
0:58
How GvHD impacts patient quality of life
Shernan Holtan • 10 Dec 2022
1:15
ASH 2022 LBA: post-transplant cyclophosphamide, tacrolimus & MMF for GvHD prophylaxis in RIC
Shernan Holtan • 10 Dec 2022
1:20
Repurposing drugs for the treatment of acute GvHD
Shernan Holtan • 25 Apr 2022

Related Videos

3:12
Addressing cardiotoxicity following CAR-T therapy and improving clinical practice
Arjun Ghosh • 25 Apr 2024
4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals